⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11691104 | 0.72 | — | — | |
| SCHEMBL9868986 | 0.72 | — | — | |
| SCHEMBL7202635 | 0.72 | — | — | |
| SCHEMBL11692530 | 0.69 | — | — | |
| SCHEMBL4146105 | 0.69 | — | — | |
| SCHEMBL11426676 | 0.68 | — | — | |
| SCHEMBL17788510 | 0.66 | HRH4 (0.33) | — | |
| SCHEMBL14220785 | 0.65 | — | — | |
| SCHEMBL6051450 | 0.64 | — | — | |
| SCHEMBL6051456 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005767-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20080027108-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015219-A1 | Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; acid-functional aryl substituted cyclopentanone or hydroxycyclopentane compounds | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070293561-A1 | 5-{3-[(1S,5S)-5-(3-Chloro-5-hydroxymethyl-phenoxymethyl)-4-oxo-cyclopent-2-enyl]-propyl}-thiophene-2-carboxylic acid; Treating eye diseases including glaucoma or ocular hypertension; selective prostaglandin EP2 agonists | ALLERGAN, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070281981-A1 | Glaucoma; 3-substituted pyrrolidine compounds; prostaglandin receptor modulators | ALLERGAN, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC | 2007-11-22 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |